Kinases - Advanced Strategies and Multiple Targets for Drug Discovery

by Sreten Bogdanovic, Ph.D. and Beata Langlands, Ph.D.

Published: September, 2006

The kinase-targeted drug market is forecast to reach $58.6 billion in 2010.

D&MD's Kinases: Advanced Strategies for Drug Discovery market analysis report comprehensively reviews protein kinases and assesses their importance as drug targets. Approaches to kinase drug discovery are evolving. Small molecule inhibitors now encompass rationally-designed single-target inhibitors and multi-target inhibitors developed with the aid of new screening and profiling assays. Innovative biopharmaceuticals are making inroads into the market. The range of indications for kinase-targeted drugs is expanding.

During the last five years, eight anticancer kinase inhibitors received FDA approval, including multi-kinase inhibitors, the first of which was approved by the FDA in December 2005. The launched drugs are discussed in this report, as are similar agents that are following in their track. At the same time, recent discoveries of activating and resistance kinase mutations have been driving the development of molecularly targeted anticancer therapies and we review progress in this area. An on-line survey conducted specially for this report shows that kinases (alongside GPCRs), are currently regarded as commercially the most promising targets available to the drug industry. The facts and analysis provided by this report help companies prepare themselves to exploit these targets.

Buy this report and receive:

> Results from a survey of more than 800 kinase drugs and their targets to give the reader an appreciation of the kinase drug landscape

> Current market size and forecasts to 2010 to assist the reader with formulating business plans in the kinase drug area

> Analysis on the leading indications for kinase drugs and highlights in areas of unmet needs to enable the reader to formulate a strategy for business development

> Profiles of kinase-related patenting at the US PTO to help the reader understand the area's evolving IP landscape, identify trends, improve strategic approach and discover potential collaborative partners

> Comprehensive analysis of kinase drug targets through a gene family-based approach to allow the reader to assess the drug development potential of kinases belonging to particular families

Receive answers to crucial questions in this area such as:

> Which kinase targets are being pursued by drug developers?

> Which kinase targets have attracted the greatest amount of interest from drug developers?

> What is the nature of commercial activity surrounding each major kinase target?

> Which are the most important therapeutic indications for kinase drugs?

> What are the areas of unmet need that new kinase drugs could address?

> Which companies are the most prolific developers of kinase drugs and what drugs are in their portfolios?

> Who are the most prolific assignees and which are the most frequently cited kinase patents?

Recent approvals of several first-in-class kinase inhibitors have resulted in increased recognition of kinases as an important class of drug targets. The kinase market is still at an early stage, but many trends are already evident and these are analyzed in this report. Already 145 kinase-related genes are being targeted in kinase drug development, which nonetheless leaves a large number (estimated 627) of potential targets unexplored. This report guides readers in assessing or reassesing their strategies with respect to this target class.

In order to comprehensively assess recent progress and prospects in the kinase field, several surveys were carried out exclusively for this report, involving searches of the Pharmaprojects database and the U.S. Patent and Trademark Office database, and questioning of respondents from the pharmaceutical industry. The information from the various surveys was utilized in the analysis of individual kinase targets and families to which they belong.

Sep-06 Pages 612
Table of Contents - The Author

Price